Equity Overview
Price & Market Data
Price: $0.278
Daily Change: +$0.0179 / 6.44%
Range: $0.262 - $0.278
Market Cap: $399,534,048
Volume: 2,420,605
Performance Metrics
1 Week: 2.62%
1 Month: %
3 Months: 7.87%
6 Months: -5.52%
1 Year: -41.70%
YTD: -3.86%
Company Details
Employees: 25
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.